Verona Pharma plc has announced positive headline data from a Phase IIa dose-finding clinical study using the Company’s new proprietary nebulised formulation of RPL554. RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disorder (COPD) patients in a hospital or home-care setting. Such patients typically require additional bronchodilation as well as anti-inflammatory treatment despite being on maximum doses of approved COPD medications (which often contain salbutamol).
- MedMined Surveillance Advisor named “the best technology for Infection Control and Monitoring”
- Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial